Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.81 |
| ▸ | PGR | P06401 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | AR | P10275 | 2/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | IKBKB | O14920 | 1/20 | 0.81 |
| ▸ | CHUK | O15111 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.81 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18475630 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL13929942 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL18475425 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL18380070 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL16718939 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL19308807 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL18379414 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL3754621 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL19764184 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL22028449 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210015929-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-7446097-B2 | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O (HR) | 2008-11-04 | — | — | US | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-20040198677-A1 | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2004-10-07 | — | — | US | disclosed |
| US-20030165873-A1 | For isolating ligand binding polypeptides; fusion proteins; drug screening; kits; surface plasmon resonance | GPC BIOTECH AG (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-0902789-B1 | ANDROSTENE DERIVATIVES | SOFT DRUGS INC (US) | 2002-01-23 | — | — | EP | disclosed |
| US-5981517-A | FOR TREATING INFLAMMATIONS OF EYES, EARS, SKINS, INTESTINES, MOUTHS, ASTHMA, AND ARTHRITIS IN ANIMALS | SOFT DRUGS, INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-4310466-A | ANTIINFLAMMATORY STEROIDS | SYNTEX (U.S.A.) INC. (US) | 1982-01-12 | — | — | US | disclosed |
| US-4263289-A | ANTIINFLAMMATORY STEROIDS | SYNTEX (U.S.A.) INC. (US) | 1981-04-21 | — | — | US | disclosed |
| EP-0004741-B1 | THIO ETIANIC ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE | SYNTEX (U.S.A.) INC. (US) | 1981-01-28 | — | — | EP | disclosed |
| EP-0004741-A2 | Thio etianic acid derivatives, their preparation and pharmaceutical use | SYNTEX (U.S.A.) INC. (US) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | NR3C1 2673/4885HIF1A 1350/4885CYP3A4 4348/4885 |
| US-20030165873-A1 | For isolating ligand binding polypeptides; fusion proteins; drug screening; kits; surface plasmon resonance | MST1R, PLAUR, SPR | NR3C1 3452/4885HIF1A 3247/4885CYP3A4 3040/4885 |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | NR3C1 2529/4885HIF1A 1743/4885CYP3A4 4762/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | NR3C1 3200/4885HIF1A 1124/4885CYP3A4 4605/4885 |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | NR3C1 3983/4885HIF1A 1784/4885CYP3A4 2975/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | NR3C1 4212/4885HIF1A 2864/4885CYP3A4 4437/4885 |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | NR3C1 3983/4885HIF1A 1784/4885CYP3A4 2975/4885 |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | NFATC1, GZMB, ICOS | NR3C1 2673/4885HIF1A 1350/4885CYP3A4 4348/4885 |
| US-20210015929-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | NR3C1 2529/4885HIF1A 1743/4885CYP3A4 4762/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | NR3C1 2179/4885HIF1A 1293/4885CYP3A4 4552/4885 |
| US-20040198677-A1 | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | CD14, CD40, MYD88 | NR3C1 728/4885HIF1A 4060/4885CYP3A4 2300/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | NR3C1 4142/4885HIF1A 3070/4885CYP3A4 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.